This site is intended for health professionals only

Treatment ‘extends cancer survival’


An American pharmaceutical firm has said using its experimental cancer treatment alongside chemotherapy improved progression-free-survival in lung cancer patients compared to just using chemotherapy.

Peregrine Pharmaceuticals said a mid-stage trial is testing the overall response rate to a tailor-made protein called bavituximab when it is combined with chemotherapy in patients with non-small cell lung cancer.

The median progression-free-survival rate of patients receiving bavituximab and chemotherapy was 6.5 months. The survival rate of those patients only receiving chemotherapy was 4.2 to 4.5 months. The figures were based on a 21-patient cohort of the trial.

The company also said the enrolment of the 49 patients planned for the study had been completed. Around 1.2 million people a year die of lung cancer, which is the top cause of cancer death in the world.

Copyright Press Association 2009

Peregrine Pharmaceuticals

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine